NCT00749580已完成不适用
A Pilot, Randomized, Controlled Study to Evaluate the Safety and Efficacy of Raltegravir Versus NRTIs as a Backbone in HIV-Infected Patients Switched From a Stable Boosted PI Regimen
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 46
- 试验地点
- 1
- 主要终点
- Number of Patients With Suppressed Viral Load(<75 Copies/ml)in Raltegravir 400 mg Bid vs. NRTI Backbone, Each in Combination of Boosted PI Regimen
研究概览
简要总结
The purpose of this study is to determine whether raltegravir 400 mg b.i.d. in a boosted PI regimen is as efficacious and safe as the NRTI backbone in a boosted PI regimen.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient is a male or female at least 18 years of age on the day of signing the informed consent.
- •Patient is HIV positive as determined by enzyme-linked immunosorbent assay (ELISA) or HIV PCR.
- •Patient has documented HIV RNA <75 copies/mL for at least 3 months prior to study entry while on a stable boosted PI based regimen without a change in antiretroviral therapy and with no documentation of HIV RNA > or = 75 copies/mL during this time.
- •Patient has no history of documented coronary artery disease that clinical investigator deems as clinically significant.
- •Patient has the following laboratory values within 35 days prior to the treatment phase of this study:
- •Alkaline phosphatase ≤ 5.0 x upper limit of normal
- •AST (SGOT) and ALT (SGPT) ≤ 5.0 x upper limit of normal. Patients with Hepatitis C Coinfection may be enrolled provided the patients are stable and meet all eligibility criteria.
- •Patient has no clinical evidence of active pulmonary disease; at the investigators, discretion a chest x-ray could be obtained if felt necessary.
- •Patient who is of reproductive potential agrees to use an acceptable method of birth control throughout the study.
- •Patient agrees to remain off prohibited concomitant medications as outlined in Section 3.2.1 of the protocol.
排除标准
- •Patients who are currently failing a boosted PI based regimen.
- •Patient is receiving a second line boosted PI regimen including boosted tripranavir or boosted darunavir.
- •Patients with chronic hepatitis B infection.
- •Patient has a history or current evidence of any condition, therapy, laboratory abnormality or other circumstance that might confound the results of the study, or interfere with the patient's participation for the full duration of the study, such that it is not in the best interest of the patient to participate.
- •Patient has a history of alcohol or other substance abuse that in the opinion of the investigator would interfere with patient compliance or safety.
- •Patient is currently participating or has participated in a study with an investigational compound or device within 30 days of signing informed consent.
- •Patient has ever used any experimental HIV-integrase inhibitor.
- •Patient has used systemic immunosuppressive therapy (e.g., 20 mg or more of prednisone or equivalent per day) within one month prior to treatment in this study. Short courses of corticosteroids (e.g., as for asthma exacerbation) will be allowed.
- •Patient requires hemodialysis.
- •Patient has significant hypersensitivity or other contraindication to any of the components of the study drugs.
- •Patient has chronic hepatitis, including chronic hepatitis B and/or C and has decompensated liver disease.
- •Patient is pregnant or breastfeeding, or expecting to conceive (within the duration of the study). Patient is expecting to donate eggs (within the duration of the study). Patient is expecting to donate sperm (within the duration of the study).
- •Subjects who have received investigational medications within 30 days of baseline.
研究组 & 干预措施
1: Boosted PI+RAL
Experimental
Group 1 Raltegravir 400 mg PO b.i.d. + their current boosted PI regimen Subjects in this study are HIV-Infected Patients who are on a stable boosted PI regimen; in this group are assigned to switched from their NRTIs as a Backbone to Raltegravir
干预措施: Switch NRTIs as a Backbone to Raltegravir (Drug)
结局指标
主要结局
Number of Patients With Suppressed Viral Load(<75 Copies/ml)in Raltegravir 400 mg Bid vs. NRTI Backbone, Each in Combination of Boosted PI Regimen
时间窗: at 24weeks for each patient
Number of patients with virologic suppression\< 75 copies/ ml at 24 wk,in raltegravir 400 mg bid vs. NRTI backbone, each in combination of boosted PI regimen.
次要结局
- Virologic Suppression of < 75 Copies/ml at 48 Weeks(at 48 weeks for each patient)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
TMC278-TiDP6-C153 - A Study in Healthy Volunteers Investigating the Pharmacokinetic Interaction Between TMC278 and RaltegravirHIV InfectionsNCT01288755Tibotec Pharmaceuticals, Ireland24
已完成
不适用
Pilot Study of a Raltegravir Based NRTI Sparing RegimenAcquired Immune Deficiency SyndromeAIDSHuman Immunodeficiency VirusHIV InfectionsNCT00814879Yale University60
已完成
3 期
Safety and Efficacy of E/C/F/TDF Versus RTV-Boosted ATV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment-Naive WomenAcquired Immunodeficiency SyndromeHIV InfectionsNCT01705574Gilead Sciences583
已完成
3 期
Switching From PI to RALtegravir in HIV Stable PatientsHIV InfectionsNCT00528892Hospital Clinic of Barcelona282
已完成
4 期
Kaletra-isentress Treatment EvaluationHIV InfectionsNCT00700115Emory University60